Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: A meta-analysis of observational studies

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 14, 2011, Pages

  Yoon, Chan ^a,b   Yang, Hyun Sik ^a,c   Jeon, Inpyo ^a,d   Chang, Yoosoo ^e   Park, Sang Min ^f  

^a Seoul National University College of Medicine   (South Korea)

^b Hwasung Public Health Center   (South Korea)

^c Muju Health Center and County Hospital   (South Korea)

^d Korea Health Promotion Foundation   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CANCER RISK; CASE CONTROL STUDY; CIGARETTE SMOKING; COHORT ANALYSIS; ESOPHAGUS CANCER; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY CANCER; MELANOMA; OBSERVATIONAL STUDY; PROSTATE CANCER;

EID: 80053503650     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.101497     Document Type: Article

References (65)

1. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627-36.
2. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011;12:65-82.
3. Lindholm LH, Carlberg B. Blood-pressure drugs and cancer: Much ado about nothing? Lancet Oncol 2011;12:6-8.
4. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352:179-84. (Pubitemid 28327802)
5. Koomen ER, Herings RM, Guchelaar HJ, et al. Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cancer Epidemiol 2009;33:391-5.
6. Houben MP, Coebergh JW, Herings RM, et al. The association between antihypertensive drugs and glioma. Br J Cancer 2006;94:752-6. (Pubitemid 43361910)
7. Pogoda JM, Katz J, McKean-Cowdin R, et al. Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study. Int J Cancer 2005;114:634-8. (Pubitemid 40349623)
8. Meier CR, Derby LE, Jick SS, et al. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000;160:349-53. (Pubitemid 30075217)
9. Shapiro JA, Williams MA, Weiss NS, et al. Hypertension, anti-hypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol 1999;149:521-30. (Pubitemid 29130019)
10. Vezina RM, Lesko SM, Rosenberg L, et al. Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 1998;11:1420-5. (Pubitemid 29030306)
11. McLaughlin JK, Chow WH, Mandel JS, et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 1995;63:216-21.
12. Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet 1997;349:525-8. (Pubitemid 27092790)
13. Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998;279:1000-4. (Pubitemid 28172998)
14. Stahl M, Bulpitt CJ, Palmer AJ, et al. Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2000;14:299-304. (Pubitemid 30311510)
15. Fitzpatrick AL, Daling JR, Furberg CD, et al. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001;11:534-42. (Pubitemid 33049887)
16. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001;92:2462-70. (Pubitemid 33029093)
17. Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001;358:539-44. (Pubitemid 32772729)
18. Li CI, Malone KE, Weiss NS, et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003;98:1504-13. (Pubitemid 37151507)
19. González-Perez A, Ronquist G, Garcia Rodriguez LA. Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 2004;13:581-5. (Pubitemid 39214037)
20. Perron L, Bairati I, Harel F, et al. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004;15:535-41. (Pubitemid 39070071)
21. Ronquist G, Rodriguez LA, Ruigomez A, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004;58:50-6. (Pubitemid 38057988)
22. Fryzek JP, Poulsen AH, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006;97:231-6. (Pubitemid 43945753)
23. Sjoberg T, Garcia Rodriguez LA, Lindblad M. Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin Gastroenterol Hepatol 2007;5:1160-1166.e1.
24. Assimes TL, Elstein E, Langleben A, et al. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf 2008;17:1039-49.
25. Boudreau DM, Koehler E, Rulyak SJ, et al. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008;17:3076-80.
26. Christian JB, Lapane KL, Hume AL, et al. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 2008;100:1223-32.
27. van der Knaap R, Siemes C, Coebergh JW, et al. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 2008;112:748-57. (Pubitemid 351240568)
28. Mellemgaard A, Niwa S, Mehl ES, et al. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 1994;23:923-30. (Pubitemid 24331206)
29. Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-9. (Pubitemid 26266609)
30. Fitzpatrick AL, Daling JR, Furberg CD, et al. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80:1438-47. (Pubitemid 27441018)
31. Largent JA, Bernstein L, Horn-Ross PL, et al. Hypertension, antihypertensive medication use, and breast cancer risk in the California teachers study cohort. Cancer Causes Control 2010;21:1615-24.
32. Kaae J, Boyd HA, Hansen AV, et al. Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2010;19:2942-9.
33. Rodriguez C, Jacobs EJ, Deka A, et al. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 2009;20:671-9.
34. Fryzek JP, Poulsen AH, Johnsen SP, et al. A cohort study of anti-hypertensive treatments and risk of renal cell cancer. Br J Cancer 2005;92:1302-6. (Pubitemid 40604409)
35. Yang X, Ma RC, So WY, et al. White blood cell count and renin-angiotensin system inhibitors for the risk of cancer in type 2 diabetes. Diabetes Res Clin Pract 2010;87:117-25.
36. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2009.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
38. Ernster VL. Nested case-control studies. Prev Med 1994;23:587-90. (Pubitemid 24377866)
39. Yun YH, Jung KW, Bae J-M, et al. Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study. Cancer Detect Prev 2005;29:15-24. (Pubitemid 40283494)
40. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994;309:901-911.
41. Kahn HA. The Dorn study of smoking and mortality among U.S. veterans: report on eight and one-half years of observation. Natl Cancer Inst Monogr 1966;19:1-125.
42. Lindberg H, Nielsen D, Jensen BV, et al. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004;43:142-52. (Pubitemid 38478900)
43. Hanif K, Bid HK, Konwar R. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens Res 2010;33:11-21.
44. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008;29:1675-84.
45. Kawahara Y, Sunako M, Tsuda T, et al. Angiotensin-II induces expression of the C-FOS gene though protein kinase-C activation and calcium-ion mobilization in cultured vascular smooth-muscle cells. Biochem Biophys Res Commun 1988;150:52-9. (Pubitemid 18036203)
46. Deshayes F, Nahmias C. Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab 2005;16:293-9. (Pubitemid 41206635)
47. Nogueira EF, Vargas CA, Otis M, et al. Angiotensin-II acute regulation of rapid response genes in human, bovine, and rat adrenocortical cells. J Mol Endocrinol 2007;39:365-74.
48. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 2007;39:2153-60. (Pubitemid 47484287)
49. Kwon S, Munroe X, Crawley SC, et al. Expression of connective tissue growth factor in pancreatic cancer cell lines. Int J Oncol 2007;31:693-703.
50. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel regulators of angiogenesis Pharmacol Rev 2007;59:185-205. (Pubitemid 46855439)
51. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671-9. (Pubitemid 26349171)
52. Hii SI, Nicol DL, Gotley DC, et al. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998;77:880-3. (Pubitemid 28101773)
53. Neo JH, Malcontenti-Wilson C, Muralidharan V, et al. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007;22:577-84. (Pubitemid 46434989)
54. Meredith PA, McInnes GT. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol 2010;11:819.
55. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005;18:134S-41S. (Pubitemid 41206570)
56. Walther T, Menrad A, Orzechowski H-D, et al. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003;17:2061-7. (Pubitemid 37392450)
57. Perkins JM, Davis SN. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes. 2008;15:147-52. (Pubitemid 351674095)
58. Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009;101:1272-9.
59. Arias-Vásquez A, Sayed-Tabatabaei FA, Schut AFC, et al. Angiotensin converting enzyme gene, smoking and mortality in a population-based study. Eur J Clin Invest 2005;35:444-9. (Pubitemid 40992774)
60. Arima Ha, Kiyohara Ya, Tanizaki Ya, et al. Angiotensin I-converting enzyme gene polymorphism modifies the smoking-cancer association: the Hisayama Study. Eur J Cancer Prev 2006;15:196-201.
61. Laustiola KE, Lassila R, Nurmi AK. Enhanced activation of the renin-angiotensin-aldosterone system in chronic cigarette smokers: a study of monozygotic twin pairs discordant for smoking. Clin Pharmacol Ther 1988;44:426-30. (Pubitemid 18259853)
62. Litt JZ. Drug eruption reference manual. 15th ed. New York (NY): Informa Healthcare; 2009.
63. Stern RS. Photocarcinogenicity of drugs. Toxicol Lett 1998;102-103:389-92. (Pubitemid 29021250)
64. Grove JS, Nomura A, Severon RK, et al. The association of blood pressure with cancer incidence in a prospective study. Am J Epidemiol 1991;134:942-7.
65. McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol 2000;27:115-23. (Pubitemid 30205367)